| Title |
Establishment of a novel therapeutic vector targeting the trigeminal ganglion in rats
|
|---|---|
| Published in |
Drug Design, Development and Therapy, February 2016
|
| DOI | 10.2147/dddt.s96730 |
| Pubmed ID | |
| Authors |
Kun Xu, Shi-Yin Pan, Jin-Xin Song, Xian-Ning Liu, Na An, Xuan Zheng |
| Abstract |
In the pathogenesis of herpes simplex keratitis, herpes simplex virus type 1 (HSV-1) infection begins in corneal epithelium cells and then progresses through the sensory nerve endings and finally travels up forward to the trigeminal ganglion (TG), where it remains as latent virus. The available anti-HSV therapies do not completely suppress the recurrence of active HSV-1 infection. The aim of this study was to establish a novel replication-defective (rd) HSV-1 (rdHSV) vector (rdHSV-interferon gamma [IFNγ]) that could effectively target the TG. Recombinant HSV-1 virus was inserted into a shuttle plasmid carrying IFNγ to establish the rdHSV-IFNγ vector. Safety was evaluated in vitro by 50% cellular cytotoxicity in transfected SH-SY5Y neuroblastoma cells and in vivo by Kaplan-Meier survival estimate and infection rate. Wistar rats were immunized with rdHSV-IFNγ to evaluate the TG targeting efficiency. Real-time polymerase chain reaction and Western blot assays were used to evaluate IFNγ mRNA and protein expression and rdHSV-IFNγ localization. The rdHSV-IFNγ vector was successfully constructed and showed high in vitro safety and overall survival and a corneal infection rate similar to that of control rats immunized with saline (control group; P>0.05). Real-time polymerase chain reaction and immunohistochemistry assays confirmed IFNγ expression and effective TG targeting on days 14 and 21, which increased with postimmunization time. Moreover, IFNγ was expressed sufficiently in the TG tissues. The rdHSV-IFNγ can act as an effective gene transporting vector that carries the therapeutic genes to the TG and triggers its expression. |
Mendeley readers
The data shown below were compiled from readership statistics for 9 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 9 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 2 | 22% |
| Other | 1 | 11% |
| Librarian | 1 | 11% |
| Student > Ph. D. Student | 1 | 11% |
| Student > Bachelor | 1 | 11% |
| Other | 0 | 0% |
| Unknown | 3 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 3 | 33% |
| Biochemistry, Genetics and Molecular Biology | 1 | 11% |
| Immunology and Microbiology | 1 | 11% |
| Agricultural and Biological Sciences | 1 | 11% |
| Unknown | 3 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 February 2016.
All research outputs
#22,935,114
of 25,576,275 outputs
Outputs from Drug Design, Development and Therapy
#1,760
of 2,274 outputs
Outputs of similar age
#349,004
of 407,504 outputs
Outputs of similar age from Drug Design, Development and Therapy
#74
of 90 outputs
Altmetric has tracked 25,576,275 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,274 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 407,504 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 90 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.